Cannabinoid receptor G protein-coupling and inverse agonism

Current Neuropharmacology

Volumn 2, Issue 1, 2004, Pages 31-36

  Lewis, Deborah L ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CANNABINOL; CP 272871; DEXANABINOL; G PROTEIN COUPLED RECEPTOR; HYDROGEN; LYSINE; MEMBRANE PROTEIN; O 1184; RIMONABANT; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

BINDING AFFINITY; HUMAN; HYDROGEN BOND; NONHUMAN; PROTEIN CONFORMATION; PROTEIN LOCALIZATION; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 3042611440     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570159043476891     Document Type: Review

References (55)

1. Ameri, A., Wilhelm, A. Simmet, T. (1999) Effects of the endogeneous cannabinoid, anandamide, on neuronal activity in rat hippocampal slices. Br. J. Pharmacol. 126, 1831-1839.
2. Auclair, N., Otani, S., Soubrie, P. Crepel, F. (2000) Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. J. Neurophysiol. 83, 3287-3293.
3. Bouaboula, M., Perrachon, S., Milligan, L., Canat, X., Rinaldi-Carmona, M., Portier, M., Barth, F., Calandra, B., Pecceu, F., Lupker, J., Maffrand, J.P., Le Fur, G. Casellas, P. (1997) A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem. 272, 22330-22339.
4. Chapman, V. (1999) The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat. Br. J. Pharmacol. 127, 1765-1767.
5. Chen, K., Ratzliff, A., Hilgenberg, L., Gulyás, A., Freund, R.F., Smith, M., Dinh, T.P., Piomelli, D., Mackie, K. Soltesz, I. (2003) Long-term plasticity of endocannabinoid signaling induced by developmental febrile seizures. Neuron 39, 599-611.
6. Chidiac, P., Hebert, T.E., Valiquette, M., Dennis, M. Bouvier, M. (1994) Inverse agonist activity of beta-adrenergic antagonists. Mol. Pharmacol. 45, 490-499.
7. Colombo, G., Agabio, R., Diaz, G., Lobina, C., Reali, R. Gessa, G.L. (1998) Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci. 63, PL113-117.
8. Costa, T., Ogino, Y., Munson, P.J., Onaran, H.O. Rodbard, D. (1992) Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. Mol. Pharmacol. 41, 549-560.
9. Coutts, A.A., Brewster, N., Ingram, T., Razdan, R.K. Pertwee, R.G. (2000) Comparison of novel cannabinoid partial agonists and SR141716A in the guinea-pig small intestine. Br. J. Pharmacol. 129, 645-652.
10. Coutts, A.A. Pertwee, R.G. (1997) Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br. J. Pharmacol. 121, 1557-1566.
11. Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A. Mechoulam, R. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949.
12. Felder, C.C., Joyce, K.E., Briley, E.M., Mansouri, J., Mackie, K., Blond, O., Lai, Y., Ma, A.L. Mitchell, R.L. (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors, Mol. Pharmacol. 48, 443-450.
13. Gerdeman, G.L., Ronesi, J. Lovinger, D.M. (2002) Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat. Neurosci. 5, 446-451.
14. Gessa, G.L., Casu, M.A., Carta, G. Mascia, M.S. (1998) Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A. Eur. J. Pharmacol. 355, 119-124.
15. Gifford, A.N. Ashby, C.R., Jr. (1996) Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. J. Pharmacol. Exp. Ther. 277, 1431-1436.
16. Herkenham, M., Lynn, A.B., Johnson, M.R., Melvin, L.S., de Costa, B.R. Rice, K.C. (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11, 563-583.
17. Herkenham, M., Lynn, A.B., Little, M.D., Johnson, M.R., Melvin, L.S., de Costa, B.R. Rice, K.C. (1990) Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. U. S. A. 87, 1932-1936.
18. Hohmann, A.G., Tsou, K. Walker, J.M. (1999) Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. J. Neurophysiol. 81, 575-583.
19. Hurst, D.P., Lynch, D.L., Barnett-Norris, J., Hyatt, S.M., Seltzman, H.H., Zhong, M., Song, Z.H., Nie, J., Lewis, D. Reggio, P.H. (2002) N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)- 4- methyl -1 H -pyrazole- 3- carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol. Pharmacol. 62, 1274-1287.
20. Izzo, A.A., Mascolo, N., Borrelli, F. Capasso, F. (1998) Excitatory transmission to the circular muscle of the guinea-pig ileum: evidence for the involvement of cannabinoid CB1 receptors. Br. J. Pharmacol. 124, 1363-1368.
21. Kathmann, M., Weber, B. Schlicker, E. (2001) Cannabinoid CB1 receptor-mediated inhibition of acetylcholine release in the brain of NMR1, CD-1 and C57BL/6J mice. Naunyn Schmiedebergs Arch. Pharmacol. 363, 50-56.
22. Kearn, C.S., Greenberg, M.J., DiCamelli, R., Kurzawa, K. Hillard, C.J. (1999) Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange. J. Neurochem. 72, 2379-2387.
23. Kenakin, T. (1996) The classification of seven transmembrane receptors in recombinant expression systems. Pharmacol. Rev. 48, 413-463.
24. Kreitzer, A.C., Carter, A.G. Regehr, W.G. (2002) Inhibition of interneuron firing extends the spread of endocannabinoid signaling in the cerebellum. Neuron 34, 787-796.
25. Landsman, R.S., Burkey, T.H., Consroe, P., Roeske, W.R. Yamamura, H.I. (1997) SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur. J. Pharmacol. 334, R1-2.
26. Landsman, R.S., Makriyannis, A., Deng, H., Consroe, P., Roeske, W.R. Yamamura, H.I. (1998) AM630 is an inverse agonist at the human cannabinoid CB1 receptor. Life Sci. 62, PL109-113.
27. Leff, P. (1995) The two-state model of receptor activation. Trends Pharmacol. Sci. 16, 89-97.
28. Levenes, C., Daniel, H., Soubrie, P. Crepel, F. (1998) Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells. J. Physiol. 510 (Pt 3), 867-879.
29. Lichtman, A.H. (2000) SR 141716A enhances spatial memory as assessed in a radial-arm maze task in rats. Eur. J. Pharmacol. 404, 175-179.
30. Mackie, K., Lai, Y., Westenbroek, R., Mitchell, R. (1995) Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. 15, 6552-6561.
31. MacLennan, S.J., Reynen, P.H., Kwan, J., Bonhaus, D.W. (1998) Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. Br. J. Pharmacol. 124, 619-622.
32. Meschler, J.P., Kraichely, D.M., Wilken, G.H., Howlett, A.C. (2000) Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid pherylamide (CP-272871) for the CB(1) cannabinoid receptor. Biochem. Pharmacol. 60, 1315-1323.
33. Milligan, G., Bond, R.A., Lee, M. (1995) Inverse agonism: pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol. Sci. 16, 10-13.
34. Mukhopadhyay, S., Howlett, A.C. (2001) CB1 receptor-G protein association. Subtype selectivity is determined by distinct intracellular domains. Eur. J. Biochem. 268, 499-505.
35. Mukhopadhyay, S., McIntosh, H.H., Houston, D.B., Howlett, A.C. (2000) The CB(1) cannabinoid receptor juxtamembrane C-terminal peptide confers activation to specific G proteins in brain. Mol. Pharmacol. 57, 162-170.
36. Ooms, F., Wouters, J., Oscari, O., Happaerts, T., Bouchard, G., Carrupt, P.A., Testa, B., Lambert, D.M. (2002) Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB(1) cannabinoid receptor ligands and potential antagonists: synthesis, lipophilicity, affinity, and molecular modeling. J. Med. Chem. 45, 1748-1756.
37. Pan, X., Ikeda, S.R., Lewis, D.L. (1996) Rat brain cannabinoid receptor modulates N-type Ca2+ channels in a neuronal expression system. Mol. Pharmacol. 49, 707-714.
38. Pan, X., Ikeda, S.R., Lewis, D.L. (1998) SR 141716A acts as an inverse agonist to increase neuronal voltage- dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity. Mol. Pharmacol. 54, 1064-1072.
39. Pertwee, R.G., Fernando, S.R. (1996) Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder. Br. J. Pharmacol. 118, 2053-2058.
40. Petitet, F., Jeantaud, B., Capet, M., Doble, A. (1997) Interaction of brain cannabinoid receptors with guanine nucleotide binding protein: a radioligand binding study. Biochem. Pharmacol. 54, 1267-1270.
41. Richardson, J.D., Aanonsen, L., Hargreaves, K.M. (1997) SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur. J. Pharmacol. 319, R3-4.
42. Rinaldi-Carmona, M., Barth, F., Millan, J., Derocq, J.M., Casellas, P., Congy, C., Oustric, D., Sarran, M., Bouaboula, M., Calandra, B., Portier, M., Shire, D., Breliere, J.C., Le Fur, G.L. (1998) SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284, 644-650.
43. Samama, P., Pei, G., Costa, T., Cotecchia, S., Lefkowitz, R.J. (1994) Negative antagonists promote an inactive conformation of the beta 2-adrenergic receptor. Mol. Pharmacol. 45, 390-394.
44. Santucci, V., Storme, J.J., Soubrie, P., Le Fur, G. (1996) Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sci. 58, PL103-110.
45. Schlicker, E., Timm, J., Zentner, J., Gothert, M. (1997) Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus. Naunyn Schmiedebergs Arch. Pharmacol. 356, 583-589.
46. Seifert, R., Wenzel-Seifert, K. (2002) Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch. Pharmacol. 366, 381-416.
47. Shen, M., Thayer, S.A. (1999) Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Mol. Pharmacol. 55, 8-13.
48. Shim, J.Y., Welsh, W.J., Cartier, E., Edwards, U., Howlett, A.C. (2002) Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor. J. Med. Chem. 45, 1447-1459.
49. Sim-Selley, L.J., Brunk, L.K., Selley, D.E. (2001) Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur. J. Pharmacol. 414, 135-143.
50. Singh, R., Hurst, D.P., Barnett-Norris, J., Lynch, D.L., Reggio, P.H., Guarnieri, F. (2002) Activation of the cannabinoid CB1 receptor may involve a W6.48/F3.36 rotamer toggle switch. J. Pept. Res. 60, 357-370.
51. Stella, N., Schweitzer, P., Piomelli, D. (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773-778.
52. Strangman, N.M., Patrick, S.L., Hohmann, A.G., Tsou, K., Walker, J.M. (1998) Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity. Brain Res. 813, 323-328.
53. Terranova, J.P., Storme, J.J., Lafon, N., Perio, A., Rinaldi-Carmona, M., Le Fur, G., Soubrie, P. (1996) Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology 126, 165-172.
54. Vasquez, C., Lewis, D.L. (1999) The CB1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors. J. Neurosci. 19, 9271-9280.
55. Wilson, R.I., Nicoll, R.A. (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410, 588-592.